3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Tumor-Agnostic
1
Plasma cell
1
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
9
Multiple Myeloma
6
Glioma
6
Neoplasm Metastasis
5
Lymphoma
5
Hematologic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Neurofibromatosis 1
4
Pancreatic Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Neurofibroma, Plexiform
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Glioblastoma
2
Brain Neoplasms
2
Astrocytoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
pembrolizumab
36
Bevacizumab
25
Cyclophosphamide
22
Blood Specimen Collection
18
Nivolumab
17
Carboplatin
15
Standard of Care
14
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
11
Fluorouracil
11
Doxorubicin
11
Cisplatin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Biopsy
8
130-nm albumin-bound paclitaxel
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms
×
trametinib
×
90 days
×
Clear all
NCT03899155
2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT01682083
2026-04-21
COMBI-AD
Novartis
Phase 3
Completed
870 enrolled
15 charts
1 FDA